Sex hormone binding globulin mRNA in human breast cancer: Detection in cell lines and tumor samples

1996 ◽  
Vol 59 (3-4) ◽  
pp. 297-304 ◽  
Author(s):  
Katherine H. Moore ◽  
Kenneth A. Bertram ◽  
Richard R. Gomez ◽  
M.J. Styner ◽  
Louis A. Matej
1979 ◽  
Vol 190 (2) ◽  
pp. 133-138 ◽  
Author(s):  
YOICHI MURAYAMA ◽  
JOJI UTSUNOMIYA ◽  
ISAMU TAKAHASHI ◽  
MASATSUGU KITAMURA ◽  
TAKESHI TOMINAGA

Diagnostics ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 757
Author(s):  
Jakub Surmacki

Titanium dioxide (TiO2) is commonly used as a pigment in paints, paper products, polymer compositions, and cosmetic products, and even as a food additive or drug coating material. In recent times, it has also been used in photovoltaic cells, semiconductors, biomedical devices, and air purification. In this paper, the potential application of nitrogen-doped TiO2 nanoparticles modified by an electron beam for improving human breast cancer detection by Raman spectroscopy is presented. Raman spectroscopy (RS) is a promising noninvasive analytical technique in cancer detection that enables us to retrieve a molecular signature of the biochemical composition of cancerous tissue. However, RS still has some challenges in signal detection, mainly related to strong concurrent background fluorescence from the analyzed tissue. The Raman signal scattering is several orders of magnitude smaller than the fluorescence intensity, and strong fluorescence masks a much weaker Raman signal. The Raman results demonstrate that the N-doped TiO2 electron beam-irradiated nanoparticles amplify the Raman scattering. The intrinsic properties of the adsorbed molecules from human breast tissue and the surface properties of the N-doped TiO2 electron beam-irradiated nanoparticles (the excited electron–hole pair at the surface) have a significant effect on the enhanced Raman signal intensity.


2014 ◽  
Vol 406 (22) ◽  
pp. 5425-5432 ◽  
Author(s):  
Chao Zheng ◽  
Lijia Liang ◽  
Shuping Xu ◽  
Haipeng Zhang ◽  
Chengxu Hu ◽  
...  

2012 ◽  
Author(s):  
Yang Pu ◽  
Guichen Tang ◽  
B. B. Das ◽  
C.-H. Liu ◽  
Asima Pradhan ◽  
...  

Animals ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 502
Author(s):  
Filipe Almeida ◽  
Andreia Gameiro ◽  
Jorge Correia ◽  
Fernando Ferreira

Feline mammary carcinoma (FMC) is the third most common type of neoplasia in cats, sharing similar epidemiological features with human breast cancer. In humans, histone deacetylases (HDACs) play an important role in the regulation of gene expression, with HDAC inhibitors (HDACis) disrupting gene expression and leading to cell death. In parallel, microtubules inhibitors (MTIs) interfere with the polymerization of microtubules, leading to cell cycle arrest and apoptosis. Although HDACis and MTIs are used in human cancer patients, in cats, data is scarce. In this study, we evaluated the antitumor properties of six HDACis (CI-994, panobinostat, SAHA, SBHA, scriptaid, and trichostatin A) and four MTIs (colchicine, nocodazole, paclitaxel, and vinblastine) using three FMC cell lines (CAT-MT, FMCp, and FMCm), and compared with the human breast cancer cell line (SK-BR-3). HDACis and MTIs exhibited dose-dependent antitumor effects in FMC cell lines, and for all inhibitors, the IC50 values were determined, with one feline cell line showing reduced susceptibility (FMCm). Immunoblot analysis confirmed an increase in the acetylation status of core histone protein HDAC3 and flow cytometry showed that HDACis and MTIs lead to cellular apoptosis. Overall, our study uncovers HDACis and MTIs as promising anti-cancer agents to treat FMCs.


Sign in / Sign up

Export Citation Format

Share Document